Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 191 entries
Sorted by: Best Match Show Resources per page
Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries.

BMJ global health

Anand S, Zheng Y, Montez-Rath ME, Wei WJ, Perico N, Carminati S, Narayan KV, Tandon N, Mohan V, Jha V, Zhang L, Remuzzi G, Prabahkaran D, Chertow GM.
PMID: 29071132
BMJ Glob Health. 2017 Oct 09;2(4):e000453. doi: 10.1136/bmjgh-2017-000453. eCollection 2017.

Kidney biopsies to elucidate the cause of chronic kidney disease (CKD) are performed in a minority of persons with CKD living in high-income countries, since associated conditions-that is, diabetes mellitus, vascular disease or obesity with pre-diabetes, prehypertension or dyslipidaemia-can...

Cite
Anand S, Zheng Y, Montez-Rath ME, et al. Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Glob Health. 2017;2(4):e000453doi: 10.1136/bmjgh-2017-000453.
Anand, S., Zheng, Y., Montez-Rath, M. E., Wei, W. J., Perico, N., Carminati, S., Narayan, K. V., Tandon, N., Mohan, V., Jha, V., Zhang, L., Remuzzi, G., Prabahkaran, D., & Chertow, G. M. (2017). Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ global health, 2(4), e000453. https://doi.org/10.1136/bmjgh-2017-000453
Anand, Shuchi, et al. "Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries." BMJ global health vol. 2,4 (2017): e000453. doi: https://doi.org/10.1136/bmjgh-2017-000453
Anand S, Zheng Y, Montez-Rath ME, Wei WJ, Perico N, Carminati S, Narayan KV, Tandon N, Mohan V, Jha V, Zhang L, Remuzzi G, Prabahkaran D, Chertow GM. Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Glob Health. 2017 Oct 09;2(4):e000453. doi: 10.1136/bmjgh-2017-000453. eCollection 2017. PMID: 29071132; PMCID: PMC5640036.
Copy Download .nbib Format: NLM
CSA and CSB play a role in the response to DNA breaks.

Oncotarget

Pascucci B, Fragale A, Marabitti V, Leuzzi G, Calcagnile AS, Parlanti E, Franchitto A, Dogliotti E, D'Errico M.
PMID: 29545921
Oncotarget. 2018 Jan 29;9(14):11581-11591. doi: 10.18632/oncotarget.24342. eCollection 2018 Feb 20.

CS proteins have been involved in the repair of a wide variety of DNA lesions. Here, we analyse the role of CS proteins in DNA break repair by studying histone H2AX phosphorylation in different cell cycle phases and DNA...

Cite
Pascucci B, Fragale A, Marabitti V, et al. CSA and CSB play a role in the response to DNA breaks. Oncotarget. 2018;9(14):11581-11591doi: 10.18632/oncotarget.24342.
Pascucci, B., Fragale, A., Marabitti, V., Leuzzi, G., Calcagnile, A. S., Parlanti, E., Franchitto, A., Dogliotti, E., & D'Errico, M. (2018). CSA and CSB play a role in the response to DNA breaks. Oncotarget, 9(14), 11581-11591. https://doi.org/10.18632/oncotarget.24342
Pascucci, Barbara, et al. "CSA and CSB play a role in the response to DNA breaks." Oncotarget vol. 9,14 (2018): 11581-11591. doi: https://doi.org/10.18632/oncotarget.24342
Pascucci B, Fragale A, Marabitti V, Leuzzi G, Calcagnile AS, Parlanti E, Franchitto A, Dogliotti E, D'Errico M. CSA and CSB play a role in the response to DNA breaks. Oncotarget. 2018 Jan 29;9(14):11581-11591. doi: 10.18632/oncotarget.24342. eCollection 2018 Feb 20. PMID: 29545921; PMCID: PMC5837770.
Copy Download .nbib Format: NLM
Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases.

Journal of pharmacology & pharmacotherapeutics

Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V, Scorcia V.
PMID: 24347979
J Pharmacol Pharmacother. 2013 Dec;4:S38-42. doi: 10.4103/0976-500X.120947.

Macular degeneration is the leading cause of blindness in developed countries. In the treatment of neovascular age-related macular degeneration, vascular endothelial growth factor (VEGF) has emerged as a key target for therapy. The intravitreal injection of anti-VEGF drugs has...

Cite
Ventrice P, Leporini C, Aloe JF, et al. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother. 2013;4:S38-42doi: 10.4103/0976-500X.120947.
Ventrice, P., Leporini, C., Aloe, J. F., Greco, E., Leuzzi, G., Marrazzo, G., Scorcia, G. B., Bruzzichesi, D., Nicola, V., & Scorcia, V. (2013). Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. Journal of pharmacology & pharmacotherapeutics, 4S38-42. https://doi.org/10.4103/0976-500X.120947
Ventrice, Pasquale, et al. "Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases." Journal of pharmacology & pharmacotherapeutics vol. 4 (2013): S38-42. doi: https://doi.org/10.4103/0976-500X.120947
Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V, Scorcia V. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother. 2013 Dec;4:S38-42. doi: 10.4103/0976-500X.120947. PMID: 24347979; PMCID: PMC3853666.
Copy Download .nbib Format: NLM
Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?.

Clinical kidney journal

Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F.
PMID: 27679716
Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 09.

A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as epidemiological and clinical research settings. It is recommended by Kidney Disease: Improving Global Outcomes guidelines in specific populations (anorectic, cirrhotic, obese,...

Cite
Delanaye P, Melsom T, Ebert N, et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. Clin Kidney J. 2016;9(5):700-4doi: 10.1093/ckj/sfw071.
Delanaye, P., Melsom, T., Ebert, N., Bäck, S. E., Mariat, C., Cavalier, E., Björk, J., Christensson, A., Nyman, U., Porrini, E., Remuzzi, G., Ruggenenti, P., Schaeffner, E., Soveri, I., Sterner, G., Eriksen, B. O., & Gaspari, F. (2016). Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. Clinical kidney journal, 9(5), 700-4. https://doi.org/10.1093/ckj/sfw071
Delanaye, Pierre, et al. "Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?." Clinical kidney journal vol. 9,5 (2016): 700-4. doi: https://doi.org/10.1093/ckj/sfw071
Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 09. PMID: 27679716; PMCID: PMC5036903.
Copy Download .nbib Format: NLM
Thrombotic microangiopathy.

European journal of internal medicine

Pisoni R, Remuzzi G.
PMID: 10854818
Eur J Intern Med. 2000 Jun;11(3):135-139. doi: 10.1016/s0953-6205(00)00083-2.

The term 'thrombotic microangiopathy' (TMA) describes syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation. The term 'hemolytic uremic syndrome' (HUS) has entered clinical use to describe childhood cases...

Cite
Pisoni R, Remuzzi G. Thrombotic microangiopathy. Eur J Intern Med. 2000;11(3):135-139doi: 10.1016/s0953-6205(00)00083-2.
Pisoni, R., & Remuzzi, G. (2000). Thrombotic microangiopathy. European journal of internal medicine, 11(3), 135-139. https://doi.org/10.1016/s0953-6205(00)00083-2
Pisoni, and Remuzzi. "Thrombotic microangiopathy." European journal of internal medicine vol. 11,3 (2000): 135-139. doi: https://doi.org/10.1016/s0953-6205(00)00083-2
Pisoni R, Remuzzi G. Thrombotic microangiopathy. Eur J Intern Med. 2000 Jun;11(3):135-139. doi: 10.1016/s0953-6205(00)00083-2. PMID: 10854818.
Copy Download .nbib Format: NLM
Mechanisms of progression of chronic renal disease.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

Pisoni R, Aros C, Ruggenenti P, Remuzzi G.
PMID: 18209421
Saudi J Kidney Dis Transpl. 2002 Jul-Sep;13(3):250-6.

Many patients with proteinuric chronic nephropathies progress relentlessly to end-stage renal failure (ESRF). Research in animal and human models has helped to identify the mechanisms involved in this progression and to indicate effective intervention. We review the main factors...

Cite
Pisoni R, Aros C, Ruggenenti P, et al. Mechanisms of progression of chronic renal disease. Saudi J Kidney Dis Transpl. 2002;13(3):250-6
Pisoni, R., Aros, C., Ruggenenti, P., & Remuzzi, G. (2002). Mechanisms of progression of chronic renal disease. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 13(3), 250-6.
Pisoni, Roberto, et al. "Mechanisms of progression of chronic renal disease." Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia vol. 13,3 (2002): 250-6.
Pisoni R, Aros C, Ruggenenti P, Remuzzi G. Mechanisms of progression of chronic renal disease. Saudi J Kidney Dis Transpl. 2002 Jul-Sep;13(3):250-6. PMID: 18209421.
Copy Download .nbib Format: NLM
[Surgical treatment of Crohn's disease. Indication and management in 20 patients].

Minerva gastroenterologica e dietologica

Contessini Avesani E, Vicentini L, Carrara A, Botti F, Reduzzi R, Dallera P.
PMID: 16495879
Minerva Gastroenterol Dietol. 1998 Mar;44(1):17-21.

MATERIALS AND METHODS: Sixty-seven patients with Crohn's disease underwent surgery in our department in the period 1989-1996. In this paper we evaluated only the first 20 patients. Ten were female and 10 male. There was single localization in 13...

Cite
Contessini Avesani E, Vicentini L, Carrara A, et al. Trattamento chirurgico del morbo di Chron. Indicazioni e tattica chirurgica in 20 pazienti. [Surgical treatment of Crohn's disease. Indication and management in 20 patients]. Minerva Gastroenterol Dietol. 1998;44(1):17-21
Contessini Avesani, E., Vicentini, L., Carrara, A., Botti, F., Reduzzi, R., & Dallera, P. (1998). Trattamento chirurgico del morbo di Chron. Indicazioni e tattica chirurgica in 20 pazienti. [Surgical treatment of Crohn's disease. Indication and management in 20 patients]. Minerva gastroenterologica e dietologica, 44(1), 17-21.
Contessini Avesani, E, et al. "Trattamento chirurgico del morbo di Chron. Indicazioni e tattica chirurgica in 20 pazienti." [Surgical treatment of Crohn's disease. Indication and management in 20 patients]. Minerva gastroenterologica e dietologica vol. 44,1 (1998): 17-21.
Contessini Avesani E, Vicentini L, Carrara A, Botti F, Reduzzi R, Dallera P. Trattamento chirurgico del morbo di Chron. Indicazioni e tattica chirurgica in 20 pazienti. [Surgical treatment of Crohn's disease. Indication and management in 20 patients]. Minerva Gastroenterol Dietol. 1998 Mar;44(1):17-21. Italian. PMID: 16495879.
Copy Download .nbib Format: NLM
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation.

Journal of transplantation

Gennarini A, Cravedi P, Marasà M, Perna A, Rota G, Bontempelli M, Sandrini S, Remuzzi G, Ruggenenti P.
PMID: 22685630
J Transplant. 2012;2012:426042. doi: 10.1155/2012/426042. Epub 2012 May 20.

Dual induction with low doses of rabbit anti-human thymoglobulin (RATG) and basiliximab effectively and safely prevented allograft rejection in high-risk renal transplant recipients. To assess whether treatment timing affects efficacy and tolerability, in this single-center, matched-cohort study, we compared...

Cite
Gennarini A, Cravedi P, Marasà M, et al. Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant. 2012;2012:426042doi: 10.1155/2012/426042.
Gennarini, A., Cravedi, P., Marasà, M., Perna, A., Rota, G., Bontempelli, M., Sandrini, S., Remuzzi, G., & Ruggenenti, P. (2012). Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. Journal of transplantation, 2012426042. https://doi.org/10.1155/2012/426042
Gennarini, Alessia, et al. "Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation." Journal of transplantation vol. 2012 (2012): 426042. doi: https://doi.org/10.1155/2012/426042
Gennarini A, Cravedi P, Marasà M, Perna A, Rota G, Bontempelli M, Sandrini S, Remuzzi G, Ruggenenti P. Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant. 2012;2012:426042. doi: 10.1155/2012/426042. Epub 2012 May 20. PMID: 22685630; PMCID: PMC3364007.
Copy Download .nbib Format: NLM
The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study.

PharmacoEconomics - open

Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio Paparatti U, Concas G, Remuzzi G.
PMID: 29623638
Pharmacoecon Open. 2018 Dec;2(4):459-467. doi: 10.1007/s41669-017-0062-z.

BACKGROUND: Chronic kidney disease (CKD) is an important public health problem. Most of the evidence on its costs relates to patients receiving dialysis or kidney transplants, which shows that, in these phases, CKD poses a high burden to payers....

Cite
Jommi C, Armeni P, Battista M, et al. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. Pharmacoecon Open. 2018;2(4):459-467doi: 10.1007/s41669-017-0062-z.
Jommi, C., Armeni, P., Battista, M., di Procolo, P., Conte, G., Ronco, C., Cozzolino, M., Costanzo, A. M., di Luzio Paparatti, U., Concas, G., Remuzzi, G. (2018). The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. PharmacoEconomics - open, 2(4), 459-467. https://doi.org/10.1007/s41669-017-0062-z
Jommi, Claudio, et al. "The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study." PharmacoEconomics - open vol. 2,4 (2018): 459-467. doi: https://doi.org/10.1007/s41669-017-0062-z
Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio Paparatti U, Concas G, Remuzzi G. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. Pharmacoecon Open. 2018 Dec;2(4):459-467. doi: 10.1007/s41669-017-0062-z. PMID: 29623638; PMCID: PMC6249198.
Copy Download .nbib Format: NLM
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Frontiers in genetics

Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P.
PMID: 31428128
Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019.

Complement activation has been increasingly implicated in the pathogenesis of type 2 diabetes and its chronic complications. It is unknown whether complement factor H (CFH) genetic variants, which have been previously associated with complement-mediated organ damage likely due to...

Cite
Valoti E, Noris M, Perna A, et al. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Front Genet. 2019;10:681doi: 10.3389/fgene.2019.00681.
Valoti, E., Noris, M., Perna, A., Rurali, E., Gherardi, G., Breno, M., Parvanova Ilieva, A., Petrov Iliev, I., Bossi, A., Trevisan, R., Dodesini, A. R., Ferrari, S., Stucchi, N., Benigni, A., Remuzzi, G., & Ruggenenti, P. (2019). Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in genetics, 10681. https://doi.org/10.3389/fgene.2019.00681
Valoti, Elisabetta, et al. "Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes." Frontiers in genetics vol. 10 (2019): 681. doi: https://doi.org/10.3389/fgene.2019.00681
Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019. PMID: 31428128; PMCID: PMC6689971.
Copy Download .nbib Format: NLM
Attosecond pulse shaping using a seeded free-electron laser.

Nature

Maroju PK, Grazioli C, Di Fraia M, Moioli M, Ertel D, Ahmadi H, Plekan O, Finetti P, Allaria E, Giannessi L, De Ninno G, Spezzani C, Penco G, Spampinati S, Demidovich A, Danailov MB, Borghes R, Kourousias G, Sanches Dos Reis CE, Billé F, Lutman AA, Squibb RJ, Feifel R, Carpeggiani P, Reduzzi M, Mazza T, Meyer M, Bengtsson S, Ibrakovic N, Simpson ER, Mauritsson J, Csizmadia T, Dumergue M, Kühn S, Nandiga Gopalakrishna H, You D, Ueda K, Labeye M, Bækhøj JE, Schafer KJ, Gryzlova EV, Grum-Grzhimailo AN, Prince KC, Callegari C, Sansone G.
PMID: 32042171
Nature. 2020 Feb;578(7795):386-391. doi: 10.1038/s41586-020-2005-6. Epub 2020 Feb 10.

Attosecond pulses are central to the investigation of valence- and core-electron dynamics on their natural timescales

Cite
Maroju PK, Grazioli C, Di Fraia M, et al. Attosecond pulse shaping using a seeded free-electron laser. Nature. 2020;578(7795):386-391doi: 10.1038/s41586-020-2005-6.
Maroju, P. K., Grazioli, C., Di Fraia, M., Moioli, M., Ertel, D., Ahmadi, H., Plekan, O., Finetti, P., Allaria, E., Giannessi, L., De Ninno, G., Spezzani, C., Penco, G., Spampinati, S., Demidovich, A., Danailov, M. B., Borghes, R., Kourousias, G., Sanches Dos Reis, C. E., Billé, F., Lutman, A. A., Squibb, R. J., Feifel, R., Carpeggiani, P., Reduzzi, M., Mazza, T., Meyer, M., Bengtsson, S., Ibrakovic, N., Simpson, E. R., Mauritsson, J., Csizmadia, T., Dumergue, M., Kühn, S., Nandiga Gopalakrishna, H., You, D., Ueda, K., Labeye, M., Bækhøj, J. E., Schafer, K. J., Gryzlova, E. V., Grum-Grzhimailo, A. N., Prince, K. C., Callegari, C., & Sansone, G. (2020). Attosecond pulse shaping using a seeded free-electron laser. Nature, 578(7795), 386-391. https://doi.org/10.1038/s41586-020-2005-6
Maroju, Praveen Kumar, et al. "Attosecond pulse shaping using a seeded free-electron laser." Nature vol. 578,7795 (2020): 386-391. doi: https://doi.org/10.1038/s41586-020-2005-6
Maroju PK, Grazioli C, Di Fraia M, Moioli M, Ertel D, Ahmadi H, Plekan O, Finetti P, Allaria E, Giannessi L, De Ninno G, Spezzani C, Penco G, Spampinati S, Demidovich A, Danailov MB, Borghes R, Kourousias G, Sanches Dos Reis CE, Billé F, Lutman AA, Squibb RJ, Feifel R, Carpeggiani P, Reduzzi M, Mazza T, Meyer M, Bengtsson S, Ibrakovic N, Simpson ER, Mauritsson J, Csizmadia T, Dumergue M, Kühn S, Nandiga Gopalakrishna H, You D, Ueda K, Labeye M, Bækhøj JE, Schafer KJ, Gryzlova EV, Grum-Grzhimailo AN, Prince KC, Callegari C, Sansone G. Attosecond pulse shaping using a seeded free-electron laser. Nature. 2020 Feb;578(7795):386-391. doi: 10.1038/s41586-020-2005-6. Epub 2020 Feb 10. PMID: 32042171.
Copy Download .nbib Format: NLM
Treatment of anaemia in the "ERAS" era: how far can we go?.

Journal of thoracic disease

Rolli L, Duranti L, Leuzzi G.
PMID: 31656640
J Thorac Dis. 2019 Sep;11(9):3692-3695. doi: 10.21037/jtd.2019.09.21.

No abstract available.

Cite
Rolli L, Duranti L, Leuzzi G. Treatment of anaemia in the "ERAS" era: how far can we go?. J Thorac Dis. 2019;11(9):3692-3695doi: 10.21037/jtd.2019.09.21.
Rolli, L., Duranti, L., & Leuzzi, G. (2019). Treatment of anaemia in the "ERAS" era: how far can we go?. Journal of thoracic disease, 11(9), 3692-3695. https://doi.org/10.21037/jtd.2019.09.21
Rolli, Luigi, et al. "Treatment of anaemia in the "ERAS" era: how far can we go?." Journal of thoracic disease vol. 11,9 (2019): 3692-3695. doi: https://doi.org/10.21037/jtd.2019.09.21
Rolli L, Duranti L, Leuzzi G. Treatment of anaemia in the "ERAS" era: how far can we go?. J Thorac Dis. 2019 Sep;11(9):3692-3695. doi: 10.21037/jtd.2019.09.21. PMID: 31656640; PMCID: PMC6790430.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 191 entries